Você está no menu de acessibilidade

Utilize este identificador para citar ou criar um link para este item: http://acervodigital.unesp.br/handle/11449/67485
Registro de metadados completo
Campo DCValorIdioma
dc.contributor.authorFranco, Roberto J.S.-
dc.contributor.authorGoldflus, Suely-
dc.contributor.authorMcQuitty, Mari-
dc.contributor.authorOigman, Wille-
dc.date.accessioned2014-05-27T11:20:56Z-
dc.date.accessioned2016-10-25T18:19:02Z-
dc.date.available2014-05-27T11:20:56Z-
dc.date.available2016-10-25T18:19:02Z-
dc.date.issued2003-12-01-
dc.identifierhttp://dx.doi.org/10.1080/080380203100022399-
dc.identifier.citationBlood Pressure, Supplement, v. 12, n. 2, p. 41-47, 2003.-
dc.identifier.issn0803-8023-
dc.identifier.urihttp://hdl.handle.net/11449/67485-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/67485-
dc.description.abstractMost hypertensive patients need more than one drug to reach recommended blood-pressure targets. We investigated the effects on 24-h ambulatory blood pressure (ABP) of the angiotensin-receptor blocker, valsartan, in combination with hydrochlorothiazide (HCTZ), compared with the calcium-channel blocker amlodipine in a Brazilian population in a multicentre, double-blind, double-dummy, parallel group, controlled study in 373 patients with essential hypertension. After a 2-week washout period, patients with a mean sitting systolic blood pressure (SBP) of 160-190 mmHg were randomized to receive either valsartan 160 mg o.d., or amlodipine 5 mg o.d. for 2 weeks and subsequently force-titrated to valsartan 160 mg/HCTZ 25 mg o.d. or amlodipine 10 mg o.d. This regimen was continued until the end of the study at week 8. The primary efficacy parameter was the change from baseline to week 8 in mean 24-h SBP. Secondary endpoints were change in mean 24-h diastolic blood pressure (DBP), tolerability and safety of treatments. Valsartan/HCTZ achieved a mean reduction in systolic ABP of -19.1 ± 11.3 mmHg compared with -20.7 ± 12.0 mmHg with amlodipine (p = 0.324 for the comparison) and in diastolic ABP by -11.1 ± 7.4 mmHg vs -11.6 ± 7.2 mmHg by amlodipine (p = 0.853 for the comparison). The valsartan/HCTZ group exhibited markedly lower rates of adverse events and discontinuations than the amlodipine group. Peripheral oedemas were far more frequent with amlodipine than with valsartan/HCTZ (1.6% with valsartan/HCTZ; 16.8% with amlodipine). Thus, the valsartan 160 mg/HCTZ 25 mg combination appears to be as efficacious as amlodipine 10 mg in this patient population but better tolerated.en
dc.format.extent41-47-
dc.language.isoeng-
dc.sourceScopus-
dc.subjectAngiotensin-receptor blocker-
dc.subjectCalcium-channel blocker-
dc.subjectCombination therapy-
dc.subjectEthnicity-
dc.subjectHypertension-
dc.subjectamlodipine-
dc.subjectcreatinine-
dc.subjecthydrochlorothiazide-
dc.subjectvalsartan-
dc.subjectdrug derivative-
dc.subjecttetrazole derivative-
dc.subjectvaline-
dc.subjectadult-
dc.subjectaged-
dc.subjectantihypertensive therapy-
dc.subjectblood pressure monitoring-
dc.subjectblood pressure regulation-
dc.subjectBrazil-
dc.subjectclinical trial-
dc.subjectcontrolled clinical trial-
dc.subjectcontrolled study-
dc.subjectcreatinine blood level-
dc.subjectdiastolic blood pressure-
dc.subjectdisease severity-
dc.subjectdizziness-
dc.subjectdouble blind procedure-
dc.subjectdrug efficacy-
dc.subjectdrug safety-
dc.subjectdrug tolerability-
dc.subjectessential hypertension-
dc.subjectfemale-
dc.subjectheadache-
dc.subjectheart palpitation-
dc.subjecthuman-
dc.subjectmajor clinical study-
dc.subjectmale-
dc.subjectmulticenter study-
dc.subjectperipheral edema-
dc.subjectpriority journal-
dc.subjectrandomized controlled trial-
dc.subjectside effect-
dc.subjectblood pressure-
dc.subjectchemically induced disorder-
dc.subjectcomparative study-
dc.subjectdrug combination-
dc.subjectdrug effect-
dc.subjectedema-
dc.subjectethnology-
dc.subjecthypertension-
dc.subjectmiddle aged-
dc.subjectrace-
dc.subjecttreatment outcome-
dc.subjectAged-
dc.subjectAmlodipine-
dc.subjectBlood Pressure-
dc.subjectBlood Pressure Monitoring, Ambulatory-
dc.subjectContinental Population Groups-
dc.subjectDouble-Blind Method-
dc.subjectDrug Therapy, Combination-
dc.subjectEdema-
dc.subjectFemale-
dc.subjectHumans-
dc.subjectHydrochlorothiazide-
dc.subjectMale-
dc.subjectMiddle Aged-
dc.subjectTetrazoles-
dc.subjectTreatment Outcome-
dc.subjectValine-
dc.titleEfficacy and Tolerability of the Combination Valsartan/Hydrochlorothiazide Compared with Amlodipine in a Mild-to-moderately Hypertensive Brazilian Populationen
dc.typeoutro-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.contributor.institutionNovartis Biociências SA-
dc.contributor.institutionNovartis Pharma AG-
dc.contributor.institutionUniv. Estadual do Rio de Janeiro-
dc.description.affiliationBotucatu Medical School Department of Medicine Nephrology Division, São Paulo-
dc.description.affiliationNovartis Biociências SA, São Paulo-
dc.description.affiliationNovartis Pharma AG, Basel-
dc.description.affiliationClínica Médica Univ. Estadual do Rio de Janeiro, Rio de Janeiro-
dc.description.affiliationNovartis Biociências SA, Av. Professor Vicente Rao, 90, CEP: 04706-900 São Paulo-
dc.description.affiliationUnespBotucatu Medical School Department of Medicine Nephrology Division, São Paulo-
dc.identifier.doi10.1080/080380203100022399-
dc.rights.accessRightsAcesso restrito-
dc.relation.ispartofBlood Pressure, Supplement-
dc.identifier.scopus2-s2.0-1642512279-
Aparece nas coleções:Artigos, TCCs, Teses e Dissertações da Unesp

Não há nenhum arquivo associado com este item.
 

Itens do Acervo digital da UNESP são protegidos por direitos autorais reservados a menos que seja expresso o contrário.